Karyopharm Reports Q1 Revenue of $35.1M, Exceeding Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2026
0mins
Reports Q1 revenue $35.1M, consensus $31.4M. "As we move through 2026, Karyopharm is in a pivotal period with meaningful clinical and regulatory milestones ahead," said CEO Richard Paulson. "Through Q2 and Q3 of 2026, we expect several important developments that have the potential to create significant value for the company, while improving outcomes for patients. In endometrial cancer, we have completed enrollment in our Phase 3 XPORT-EC-042 trial and remain on track to report topline data in mid-2026. In myelofibrosis, the Phase 3 SENTRY results reinforced the potential of selinexor to meaningfully improve patient outcomes, including a statistically significant SVR35 benefit and a promising overall survival signal. With the endometrial cancer readout ahead and the myelofibrosis regulatory and guideline path coming into focus, we believe these programs could meaningfully expand the impact and long-term opportunity of the selinexor franchise."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KPTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KPTI
Wall Street analysts forecast KPTI stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 9.110
Low
6.00
Averages
13.83
High
21.00
Current: 9.110
Low
6.00
Averages
13.83
High
21.00
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Karyopharm to Host Conference Call on SENTRY Trial Results
- Conference Call Details: Karyopharm Therapeutics will host a conference call on June 2, 2026, at 2:00 p.m. ET, featuring senior management and Dr. John Mascarenhas, the principal investigator of the SENTRY trial, to discuss the results of selinexor plus ruxolitinib in myelofibrosis, which could positively impact the company's future treatment strategies.
- ASCO Meeting Preview: This call will follow Dr. Mascarenhas' oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing Karyopharm's cutting-edge research in cancer treatment, likely attracting investor interest and boosting market confidence.
- Product Market Performance: Karyopharm's lead product, XPOVIO (selinexor), is approved in the U.S. for relapsed or refractory multiple myeloma and has received approval in over 50 countries, indicating strong demand and growth potential in the global market.
- Future R&D Directions: The company is exploring the application of XPO1 inhibitors in hematologic and solid tumors, including myelofibrosis and TP53 wild-type endometrial cancer, demonstrating Karyopharm's commitment to developing innovative therapies to meet unmet medical needs.
See More
Karyopharm to Host Conference Call on SENTRY Trial Results
- Conference Call Scheduled: Karyopharm Therapeutics will host a conference call on June 2, 2026, at 2:00 p.m. ET to discuss the results of the SENTRY trial, which is expected to attract attention from investors and healthcare professionals, thereby enhancing the company's visibility in cancer treatment.
- Expert Participation: The call will feature Dr. John Mascarenhas, the principal investigator of the SENTRY trial, who will share insights from his oral presentation at the 2026 American Society of Clinical Oncology Annual Meeting, reinforcing investor confidence in the company's future developments in hematologic cancer therapies.
- Product Background: Karyopharm's lead product, XPOVIO® (selinexor), is the first-in-class exportin 1 inhibitor approved in the U.S. for relapsed or refractory multiple myeloma and has been approved in over 50 countries, showcasing its broad market potential globally.
- Future Development Directions: The company is exploring the potential of XPO1 inhibition across various hematologic malignancies and solid tumors, particularly in TP53 wild-type endometrial cancer, indicating Karyopharm's commitment to addressing unmet medical needs through innovative drug development.
See More
Karyopharm to Speak at 2026 Jefferies Global Healthcare Conference
- Management Participation: Karyopharm Therapeutics' senior management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, in New York, showcasing the company's innovative advancements in cancer therapies.
- Live Webcast Available: The fireside chat will be accessible via a live webcast on the company's website under the 'Investors & Media' section, allowing investors to engage with the company's updates and access a replay post-event.
- Leading Therapeutic Solution: Karyopharm's lead therapy, XPOVIO® (selinexor), is the first-in-class export inhibitor approved in the U.S. for relapsed or refractory multiple myeloma and in over 50 countries, highlighting its global market potential.
- Research and Development Opportunities: The company is exploring XPO1 inhibition across various hematologic and solid tumors, including myelofibrosis and TP53 wild-type endometrial cancer, indicating its ongoing innovation and expansion potential in cancer treatment.
See More
Karyopharm Therapeutics Q1 2026 Earnings Call Insights
- Clinical Trial Progress: Karyopharm reported top-line results from the Phase III SENTRY trial in Q1, with a spleen response rate of 50% for the combination therapy, significantly higher than the 28% for ruxolitinib alone, providing robust data to enhance the company's competitive position in the myelofibrosis market.
- Financial Performance Boost: Total revenue for the first quarter reached $35.1 million, up from $30 million in the prior year, primarily driven by an increase in U.S. XPOVIO net product revenue from $21.1 million to $29.2 million, indicating strong sales performance.
- Future Outlook: The company expects total revenue in the range of $130 million to $150 million for 2026, while anticipating combined R&D and SG&A expenses between $230 million and $245 million, reflecting ongoing investments in R&D to drive future growth.
- Liquidity Position: Karyopharm ended the quarter with $91.2 million in cash and cash equivalents, including approximately $50 million raised this quarter, ensuring operational flexibility through upcoming clinical and regulatory catalysts.
See More
Karyopharm Q1 Earnings Beat Expectations
- Earnings Highlights: Karyopharm Therapeutics reported a Q1 GAAP EPS of -$1.24, beating expectations by $0.25, with revenue of $35.07 million reflecting a 16.8% year-over-year increase, surpassing estimates by $3.67 million, indicating strong performance in revenue growth.
- Product Revenue Analysis: For the quarter ended March 31, 2026, U.S. net product revenue reached $29.2 million, up from $21.1 million in the same quarter of 2025, although demand for XPOVIO decreased due to new competitive entrants, highlighting challenges in market competition.
- Royalty Revenue Growth: Royalty revenue increased to $1.9 million in Q1 2026 compared to $1.7 million in Q1 2025, indicating that selinexor's approval in over 50 ex-U.S. countries and territories has strengthened the company's international market position.
- Cash Flow Status: As of March 31, 2026, the company reported total cash, cash equivalents, and restricted cash of $91.2 million, including approximately $50 million raised from private placements and open market sales, a significant increase from $64.1 million as of December 31, 2025, demonstrating positive progress in fundraising efforts.
See More
Karyopharm Reports Q1 2026 Financial Results and Clinical Progress
- Clinical Trial Progress: Karyopharm has completed enrollment in the Phase 3 XPORT-EC-042 trial for endometrial cancer, with topline data expected in mid-2026, which will establish a foundation for further advancements in cancer treatment.
- Improved Financial Performance: Total revenue for Q1 2026 was $35.1 million, a 17% increase from $30 million in Q1 2025, with net product revenue from XPOVIO at $29.2 million, indicating strong market performance and increased product demand.
- Annual Revenue Guidance Reaffirmed: The company reaffirmed its total revenue guidance for 2026 at $130 million to $150 million, including net product revenue guidance for XPOVIO at $115 million to $130 million, reflecting management's confidence in future performance and market potential.
- Operational Efficiency Improvement: The operating loss for Q1 was $26.8 million, a 20% improvement from $33.3 million in Q1 2025, demonstrating positive progress in cost management and operational efficiency, which enhances financial stability.
See More
Karyopharm to Host Conference Call on SENTRY Trial Results
- Conference Call Details: Karyopharm Therapeutics will host a conference call on June 2, 2026, at 2:00 p.m. ET, featuring senior management and Dr. John Mascarenhas, the principal investigator of the SENTRY trial, to discuss the results of selinexor plus ruxolitinib in myelofibrosis, which could positively impact the company's future treatment strategies.
- ASCO Meeting Preview: This call will follow Dr. Mascarenhas' oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing Karyopharm's cutting-edge research in cancer treatment, likely attracting investor interest and boosting market confidence.
- Product Market Performance: Karyopharm's lead product, XPOVIO (selinexor), is approved in the U.S. for relapsed or refractory multiple myeloma and has received approval in over 50 countries, indicating strong demand and growth potential in the global market.
- Future R&D Directions: The company is exploring the application of XPO1 inhibitors in hematologic and solid tumors, including myelofibrosis and TP53 wild-type endometrial cancer, demonstrating Karyopharm's commitment to developing innovative therapies to meet unmet medical needs.
See More
Karyopharm to Host Conference Call on SENTRY Trial Results
- Conference Call Scheduled: Karyopharm Therapeutics will host a conference call on June 2, 2026, at 2:00 p.m. ET to discuss the results of the SENTRY trial, which is expected to attract attention from investors and healthcare professionals, thereby enhancing the company's visibility in cancer treatment.
- Expert Participation: The call will feature Dr. John Mascarenhas, the principal investigator of the SENTRY trial, who will share insights from his oral presentation at the 2026 American Society of Clinical Oncology Annual Meeting, reinforcing investor confidence in the company's future developments in hematologic cancer therapies.
- Product Background: Karyopharm's lead product, XPOVIO® (selinexor), is the first-in-class exportin 1 inhibitor approved in the U.S. for relapsed or refractory multiple myeloma and has been approved in over 50 countries, showcasing its broad market potential globally.
- Future Development Directions: The company is exploring the potential of XPO1 inhibition across various hematologic malignancies and solid tumors, particularly in TP53 wild-type endometrial cancer, indicating Karyopharm's commitment to addressing unmet medical needs through innovative drug development.
See More
Karyopharm to Speak at 2026 Jefferies Global Healthcare Conference
- Management Participation: Karyopharm Therapeutics' senior management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, in New York, showcasing the company's innovative advancements in cancer therapies.
- Live Webcast Available: The fireside chat will be accessible via a live webcast on the company's website under the 'Investors & Media' section, allowing investors to engage with the company's updates and access a replay post-event.
- Leading Therapeutic Solution: Karyopharm's lead therapy, XPOVIO® (selinexor), is the first-in-class export inhibitor approved in the U.S. for relapsed or refractory multiple myeloma and in over 50 countries, highlighting its global market potential.
- Research and Development Opportunities: The company is exploring XPO1 inhibition across various hematologic and solid tumors, including myelofibrosis and TP53 wild-type endometrial cancer, indicating its ongoing innovation and expansion potential in cancer treatment.
See More
Karyopharm Therapeutics Q1 2026 Earnings Call Insights
- Clinical Trial Progress: Karyopharm reported top-line results from the Phase III SENTRY trial in Q1, with a spleen response rate of 50% for the combination therapy, significantly higher than the 28% for ruxolitinib alone, providing robust data to enhance the company's competitive position in the myelofibrosis market.
- Financial Performance Boost: Total revenue for the first quarter reached $35.1 million, up from $30 million in the prior year, primarily driven by an increase in U.S. XPOVIO net product revenue from $21.1 million to $29.2 million, indicating strong sales performance.
- Future Outlook: The company expects total revenue in the range of $130 million to $150 million for 2026, while anticipating combined R&D and SG&A expenses between $230 million and $245 million, reflecting ongoing investments in R&D to drive future growth.
- Liquidity Position: Karyopharm ended the quarter with $91.2 million in cash and cash equivalents, including approximately $50 million raised this quarter, ensuring operational flexibility through upcoming clinical and regulatory catalysts.
See More
Karyopharm Q1 Earnings Beat Expectations
- Earnings Highlights: Karyopharm Therapeutics reported a Q1 GAAP EPS of -$1.24, beating expectations by $0.25, with revenue of $35.07 million reflecting a 16.8% year-over-year increase, surpassing estimates by $3.67 million, indicating strong performance in revenue growth.
- Product Revenue Analysis: For the quarter ended March 31, 2026, U.S. net product revenue reached $29.2 million, up from $21.1 million in the same quarter of 2025, although demand for XPOVIO decreased due to new competitive entrants, highlighting challenges in market competition.
- Royalty Revenue Growth: Royalty revenue increased to $1.9 million in Q1 2026 compared to $1.7 million in Q1 2025, indicating that selinexor's approval in over 50 ex-U.S. countries and territories has strengthened the company's international market position.
- Cash Flow Status: As of March 31, 2026, the company reported total cash, cash equivalents, and restricted cash of $91.2 million, including approximately $50 million raised from private placements and open market sales, a significant increase from $64.1 million as of December 31, 2025, demonstrating positive progress in fundraising efforts.
See More
Karyopharm Reports Q1 2026 Financial Results and Clinical Progress
- Clinical Trial Progress: Karyopharm has completed enrollment in the Phase 3 XPORT-EC-042 trial for endometrial cancer, with topline data expected in mid-2026, which will establish a foundation for further advancements in cancer treatment.
- Improved Financial Performance: Total revenue for Q1 2026 was $35.1 million, a 17% increase from $30 million in Q1 2025, with net product revenue from XPOVIO at $29.2 million, indicating strong market performance and increased product demand.
- Annual Revenue Guidance Reaffirmed: The company reaffirmed its total revenue guidance for 2026 at $130 million to $150 million, including net product revenue guidance for XPOVIO at $115 million to $130 million, reflecting management's confidence in future performance and market potential.
- Operational Efficiency Improvement: The operating loss for Q1 was $26.8 million, a 20% improvement from $33.3 million in Q1 2025, demonstrating positive progress in cost management and operational efficiency, which enhances financial stability.
See More
